A global federated real-world data and analytics platform for research

TLDR

The article presents a scalable, performant, and sustainable global network of electronic health record data for biomedical and clinical research. TriNetX provides a secure, governance‑driven technology platform that connects industry and healthcare organizations, offering analytics, de‑identified data, and trial opportunities while industry funding supports platform growth and improves clinical trial design and deployment. The network has expanded to more than 220 healthcare organizations in 30 countries, generated over 19,000 sponsored trial opportunities, and produced more than 350 peer‑reviewed publications, demonstrating a safe, proven, and sustainable academic‑industry research model.

Abstract

Abstract Objective This article describes a scalable, performant, sustainable global network of electronic health record data for biomedical and clinical research. Materials and Methods TriNetX has created a technology platform characterized by a conservative security and governance model that facilitates collaboration and cooperation between industry participants, such as pharmaceutical companies and contract research organizations, and academic and community-based healthcare organizations (HCOs). HCOs participate on the network in return for access to a suite of analytics capabilities, large networks of de-identified data, and more sponsored trial opportunities. Industry participants provide the financial resources to support, expand, and improve the technology platform in return for access to network data, which provides increased efficiencies in clinical trial design and deployment. Results TriNetX is a growing global network, expanding from 55 HCOs and 7 countries in 2017 to over 220 HCOs and 30 countries in 2022. Over 19 000 sponsored clinical trial opportunities have been initiated through the TriNetX network. There have been over 350 peer-reviewed scientific publications based on the network’s data. Conclusions The continued growth of the TriNetX network and its yield of clinical trial collaborations and published studies indicates that this academic-industry structure is a safe, proven, sustainable path for building and maintaining research-centric data networks.